Gleostine (Lomustine) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Gleostine is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat Hodgkin lymphoma that has progressed after initial therapy. Gleostine is often combined with a chemotherapy regimen. Gleostine is also known by its drug name, lomustine. Lomustine was previously marketed as CeeNU.

Gleostine is an anticancer drug and a member of a class of drugs called alkylating agents. Gleostine is believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How do I take it?
Gleostine is taken orally once every six weeks.

Gleostine is available as a capsule.

Side effects
The FDA-approved label for Gleostine lists common side effects including nausea, vomiting, hair loss, and mouth sores. Delayed myelosuppression – decreased bone marrow activity that causes a dangerous drop in blood cell counts – is a common and dangerous side effect of taking Gleostine.

Rare but serious side effects listed for Gleostine include lung and liver damage, kidney failure, fetal harm, a risk for fatal overdose, and an increased risk for developing other cancers such as leukemia and myelodysplasia.

For more details about this treatment, visit:

Gleostine — NextSource Biotechnology

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in